Mycobacterial dihydrofolate reductase inhibitors identified using chemogenomic methods and in vitro validation

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Mugumbate, Grace ^a   Abrahams, Katherine A ^b   Cox, Jonathan A G ^b   Papadatos, George ^a   Van Westen, Gerard ^a   Lelièvre, Joël ^c   Calus, Szymon T ^b   Loman, Nicholas J ^b   Ballell, Lluis ^c   Barros, David ^c   Overington, John P ^a   Besra, Gurdyal S ^b  

^a EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c GLAXOSMITHKLINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRL 10143SA; BRL 7940SA; DIHYDROFOLATE REDUCTASE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; FOLIC ACID ANTAGONIST; LIGAND;

ANALYTIC METHOD; ARTICLE; CHEMOGENOMIC METHOD; COMPUTER MODEL; DRUG SCREENING; DRUG TARGETING; ESSENTIAL GENE; EXPERIMENTAL STUDY; IN VITRO STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; VALIDATION STUDY; CHEMISTRY; COMPUTER SIMULATION; ENZYMOLOGY; GENOMICS; HUMAN; METABOLISM; MOLECULAR DOCKING; PHENOTYPE; PRECLINICAL STUDY; PROCEDURES; PROTEIN CONFORMATION;

MYCOBACTERIUM TUBERCULOSIS;

COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; FOLIC ACID ANTAGONISTS; GENOMICS; HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; PROTEIN CONFORMATION; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 84925678948     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0121492     Document Type: Article

References (40)

1. WHO. Global Tuberculosis Control. 2011.
2. Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ. 2012; 90: 111-119D. doi: 10.2471/BLT.11.092585 PMID: 22423162
3. Warner DF, Mizrahi V. Approaches to target identification and validation for tuberculosis drug discovery: A University of Cape Town perspective. South African Medical Journal. 2012; 102: 457-460. PMID: 22668936
4. WHO. Global Tuberculosis Report. 2013.
5. Bajorath J. Integration of virtual and high-throughput screening. Nat Rev Drug Discov. 2002; 1: 882-894. PMID: 12415248
6. Bento AP, Gaulton A, Hersey A, Bellis LJ, Chambers J, et al. The ChEMBL bioactivity database: an update. Nucleic Acids Res. 2014; 42: D1083-1090. doi: 10.1093/nar/gkt1031 PMID: 24214965
7. Ballell L, Bates RH, Young RJ, Alvarez-Gomez D, Alvarez-Ruiz E, et al. Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis. ChemMedChem. 2013; 8: 313-321. doi: 10. 1002/cmdc.201200428 PMID: 23307663
8. Lipinski CA Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov Today Technol. 2004; 1: 337-341. doi: 10.1016/j.ddtec.2004.11.007 PMID: 24981612
9. Florkowski CM Sensitivity, Specificity, Receiver-Operating Characteristic (ROC) Curves and Likelihood Ratios: Communicating the Performance of Diagnostic Tests. Clin Biochem Rev. 2008; 29: S83-S87. PMID: 18852864
10. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Discovery Reviews. 1997; 23: 3-25.
11. Yamanishi Y, Araki M, Gutteridge A, Honda W, Kanehisa M. Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics. 2008; 24: i232-i240. doi: 10.1093/bioinformatics/btn162 PMID: 18586719
12. Strombergsson H, Kleywegt GJ. A chemogenomics view on protein-ligand spaces. BMC Bioinformatics 10. 2009; Suppl 6: S13. doi: 10.1186/1471-2105-10-S6-S13 PMID: 19534738
13. Mart? nez-Jimé nez F, Papadatos G, Yang L, Wallace IM, Kumar V, Pieper U, et al. Target Prediction for an Open Access Set of Compounds Active against Mycobacterium tuberculosis. PLoS Comput Biol. 2013; 9: e1003253. doi: 10.1371/journal.pcbi.1003253 PMID: 24098102
14. Ekins S, Freundlich JS, Reynolds RC. Fusing dual-event data sets for Mycobacterium tuberculosis machine learning models and their evaluation. J Chem Inf Model. 2013; 53: 3054-3063. doi: 10.1021/ ci400480s PMID: 24144044
15. Kumar M, Vijayakrishnan R, Subba Rao G. In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery. Mol Divers. 2010; 14: 595-604. doi: 10.1007/s11030-009-9172-6 PMID: 19697148
16. Dias MV, Tyrakis P, Domingues RR, Leme AF, Blundell TL. Mycobacterium tuberculosis Dihydrofolate Reductase Reveals Two Conformational States and a Possible Low Affinity Mechanism to Antifolate Drugs. Structure. 2014.
17. Kappler MA. Software for rapid prototyping in the pharmaceutical and biotechnology industries. Curr Opin Drug Discov Devel. 2008; 11: 389-392. PMID: 18428093
18. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012; 40: D1100-1107. doi: 10.1093/nar/gkr777 PMID: 21948594
19. Rogers D, Hahn M. Extended-connectivity fingerprints. J Chem Inf Model. 2010; 50: 742-754. doi: 10. 1021/ci100050t PMID: 20426451
20. Myint KZ, Wang L, Tong Q, Xie XQ. Molecular fingerprint-based artificial neural networks QSAR for ligand biological activity predictions. Mol Pharm. 2012; 9: 2912-2923. PMID: 22937990
21. Ekins S, Reynolds RC, Franzblau SG, Wan B, Freundlich JS, et al. Enhancing hit identification in Mycobacterium tuberculosis drug discovery using validated dual-event Bayesian models. PLoS One. 2013; 8: e63240. doi: 10.1371/journal.pone.0063240 PMID: 23667592
22. Nidhi, Glick M, Davies JW, Jenkins JL. Prediction of biological targets for compounds using multiplecategory Bayesian models trained on chemogenomics databases. Journal of chemical information and modeling. 2006; 46: 1124-1133. PMID: 16711732
23. Xia X, Maliski EG, Gallant P, Rogers D. Classification of Kinase Inhibitors Using a Bayesian Model. J Med Chem. 2004; 47: 4463-4470. PMID: 15317458
24. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, et al. Predicting new molecular targets for known drugs. Nature. 2009; 462: 175-181. doi: 10.1038/nature08506 PMID: 19881490
25. Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature. 2012; 486: 361-367. doi: 10.1038/nature11159 PMID: 22722194
26. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, et al. Relating protein pharmacology by ligand chemistry. Nat Biotechnol. 2007; 25: 197-206. PMID: 17287757
27. Totrov Ma AR. Flexible Protein-Ligand Docking by Global Energy Optimization in Internal Coordinates. PROTEINS: Structure, Function, and Genetics Suppl. 1997; 1: 215-220. PMID: 9485515
28. Abad-Zapatero C, Perisic O, Wass J, Bento AP, Overington J, et al. Ligand efficiency indices for an effective mapping of chemico-biological space: The concept of an atlas-like representation. Drug Discov Today. 2010; 15: 804-811. doi: 10.1016/j.drudis.2010.08.004 PMID: 20727982
29. Neves MA, Totrov M, Abagyan R. Docking and scoring with ICM: The benchmarking results and strategies for improvement. J Comput Aided Mol Des. 2012; 26: 675-686. doi: 10.1007/s10822-012-9547-0 PMID: 22569591
30. Abrahams K, Cox JAG, Spivey VL, Loman NJ, Pallen MJ, Constantinidou C, et al. Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB. PLoS One. 2012; 7: e52951. doi: 10.1371/journal.pone.0052951 PMID: 23300833
31. Rogers D, Brown RD, Hahn M. Using extended-connectivity fingerprints with Laplacian-modified Bayesian analysis in high-throughput screening follow-up. J Biomol Screen. 2005; 10: 682-686. PMID: 16170046
32. Chen B, McConnell KJ, Wale N, Wild DJ, Gifford EM. Comparing Bioassay Response and Similarity Ensemble Approaches to Probing Protein Pharmacology. Bioinformatics. 2011; 27: 3044-3049. doi: 10.1093/bioinformatics/btr506 PMID: 21903625
33. Blondeau JM. Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol. 2004; 49 Suppl 2: S73-78. PMID: 15028482
34. Mdluli K, Ma Z. Mycobacterium tuberculosis DNA Gyrase as a Target for Drug Discovery. Infectious Disorders-Drug Targets. 2007; 7: 1-10.
35. Chen F, Mackey AJ, Stoeckert CJ Jr, Roos DS. OrthoMCL-DB: querying a comprehensive multi-species collection of ortholog groups. Nucleic Acids Res. 2006; 34: D363-368. PMID: 16381887
36. Magarinos MP, Carmona SJ, Crowther GJ, Ralph SA, Roos DS, et al. TDR Targets: a chemogenomics resource for neglected diseases. Nucleic Acids Res. 2012; 40: D1118-1127. doi: 10.1093/nar/gkr1053 PMID: 22116064
37. Li R, Sirawaraporn R, Chitnumsub P, Sirawaraporn W, Wooden J, Athappilly F., et al. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. Journal of molecular biology. 2000; 295: 307-323. PMID: 10623528
38. Mdluli K, Kaneko T, Upton A. Tuberculosis drug discovery and emerging targets. Ann N Y Acad Sci: 1-20.
39. Zheng J, Rubin EJ, Bifani P, Mathys V, Lim V, et al. Para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. J Biol Chem. 2013; 288: 23447-23456. doi: 10. 1074/jbc.M113.475798 PMID: 23779105
40. Leduc D, Escartin F, Nijhout HF, Reed MC, Liebl U, Skouloubris S, et al. Flavin-Dependent Thymidylate Synthase ThyX Activity: Implications for the Folate Cycle in Bacteria. J Bacteriol. 2007; 189: 8537-8545. PMID: 17890305